CNE100003RM8
CNE100003RM8
ZHEJIANG ORIENT GENE BIOTECH CO
Loading chart...
Valuation & History
Quarterly trend of key valuation metrics
| Metric | Current (TTM) TTM Baseline | Q2 '26 30.06.2026 | Q1 '26 31.03.2026 | Q4 '25 31.12.2025 |
|---|---|---|---|---|
Market & Enterprise Value | ||||
Market Cap | 3.93B EUR | 3.6B EUR | 4.6B EUR | 4.72B EUR |
Enterprise Value | 1.88B EUR | 1.75B EUR | 2.67B EUR | 2.6B EUR |
Valuation Multiples | ||||
Trailing P/E | -- | -- | -- | -- |
Forward P/E | 0.73x | -- | -- | -- |
Price to Sales | 3.9x | 4.87x | 6.19x | 6.96x |
Price to Book | 0.65x | 0.63x | 0.78x | 0.79x |
EV/Revenue | 1.86x | 2.36x | 3.6x | 3.83x |
EV/EBITDA | -7.56x | -- | -- | -- |
Price to FCF (P/FCF) | -- | -- | -- | -- |
EV/FCF | -- | -- | -- | -- |
FCF Yield | -9.55% | -8.54% | -7.9% | -8.64% |